Payment overview · 2025
General Payments
$713.51
7 reported records · 7 companies
Healthcare provider profile · identity verified
Michael Wenbin Guo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1780649517
Verified facts
What the public records show
CMS Open Payments records show Michael Wenbin Guo, M.D. received $713.51 in general payments during 2025 across 7 reported records.
Alcon Vision LLC accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $147.33 | 20.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 17.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 17.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 17.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.18 | 16.8% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $56.82 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.18 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $713.51 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $147.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $120.18 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $56.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 547 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 168 |
| Losartan Potassium | Losartan Potassium | 319 | 114 |
| Metformin Hcl | Metformin Hcl | 303 | 103 |
| Diclofenac Epolamine | Diclofenac Epolamine | 247 | 73 |
| Simvastatin | Simvastatin | 237 | 77 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 211 | 124 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 71 |
| Omeprazole | Omeprazole | 163 | 90 |
| Azithromycin | Azithromycin | 160 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 60 |
| Meclizine Hcl | Meclizine Hcl | 152 | 91 |
| Ammonium Lactate | Ammonium Lactate | 132 | 85 |
| Vascepa | Icosapent Ethyl | 128 | 25 |
| Celecoxib | Celecoxib | 126 | 76 |
| Atenolol | Atenolol | 123 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 49 |
| Montelukast Sodium | Montelukast Sodium | 110 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 35 |
| Trazodone Hcl | Trazodone Hcl | 89 | 44 |
| Farxiga | Dapagliflozin Propanediol | 81 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 53 |
| Finasteride | Finasteride | 75 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 25 |
| Azelastine Hcl | Azelastine Hcl | 68 | 45 |
| Lisinopril | Lisinopril | 66 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 51 |
| Jardiance | Empagliflozin | 56 | 17 |
| Allopurinol | Allopurinol | 54 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 21 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 52 | 15 |
| Hydrocortisone | Hydrocortisone | 50 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 48 | 24 |
| Cromolyn Sodium | Cromolyn Sodium | 48 | 29 |
| Alendronate Sodium | Alendronate Sodium | 47 | 16 |
| Colchicine | Colchicine | 46 | 20 |
| Loperamide | Loperamide Hcl | 46 | 30 |
| Amoxicillin | Amoxicillin | 45 | 38 |
| Nitroglycerin | Nitroglycerin | 45 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | 14 |
| Glimepiride | Glimepiride | 42 | 11 |
| Mupirocin | Mupirocin | 41 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 24 |
| Donepezil Hcl | Donepezil Hcl | 38 | 14 |
| Eliquis | Apixaban | 37 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 19 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 35 |
| Furosemide | Furosemide | 35 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Naproxen | Naproxen | 28 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Prednisone | Prednisone | 27 | 21 |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 11 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 18 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | 15 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $713.51 · 7 records | Alcon Vision LLC | BREZTRI, EVENITY, HYDRUS Microstent, Ozempic, Restrata Wound Matrix, Symbravo, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error